临床荟萃

• 论著 • 上一篇    下一篇

胸苷激酶1在多发性骨髓瘤治疗及预后中的临床意义

  

  1. 甘肃省人民医院 血液科, 甘肃 兰州  730000
  • 出版日期:2019-01-20 发布日期:2019-01-30
  • 通讯作者: 通信作者:张启科,Email:zqk05@163.com
  • 基金资助:
    甘肃省人民医院院内科研项目多发性骨髓瘤多学科诊治(MDT)协作模式的建立和应用(17GSSY22)

Clinical  significance of  serum  thymidine kinase 1 in treatment and prognosis of multiple myeloma

  1. Department of Hematology, Gansu Provincial Hospital, Lanzhou 730000, China
  • Online:2019-01-20 Published:2019-01-30
  • Contact: Corresponding author: Zhang Qike,Email:zqk05@163.com

摘要: 目的 探讨胸苷激酶1(TK1)在多发性骨髓瘤(MM)治疗及预后中的临床意义。方法 入选32例MM患者、20例意义未明的单克隆免疫球蛋白血症(MGUS)患者和同期20例健康人,分析3组β2微球蛋白(β2MG)、球蛋白(GLB)、乳酸脱氢酶(LDH)和血清TK1水平差别。根据MM国际分期体系(ISS),MM组分为Ⅰ期、Ⅱ期、Ⅲ期组,分析组间β2MG、GLB、LDH和TK1水平差别,并对治疗前血清TK1和β2MG、GLB、LDH水平进行相关性分析;所有MM患者均接受化疗,比较不同疗效患者治疗前后的TK1表达水平;对不同TK1水平的MM患者中位生存期进行分析,探讨TK1在MM患者治疗及预后中的意义。结果   MM组β2MG、GLB、LDH和TK1水平高于MGUS组及健康对照组(P<0.05);Ⅲ期的β2MG、GLB、LDH、TK1高于Ⅰ期和Ⅱ期(P<0.05);治疗前血清TK1水平与β2MG、GLB、LDH呈正相关(P<0.05);有效组治疗后的TK1表达水平下降(P<0.05);KaplanMeier生存曲线显示血清TK1<4.97  pmol/L的MM患者5年累积生存率为64.7%,高于血清TK1≥4.97  pmol/L的MM患者(20.0%),差异有统计学意义(P<0.05)。结论  MM患者血清TK1水平明显升高,TK1水平对治疗效果的判定有一定参考意义,并且影响预后。

关键词: 多发性骨髓瘤, 胸苷激酶1, 意义未明的单克隆免疫球蛋白血症

Abstract: Objective  To study the clinical significance of serum thymidine kinase 1(TK1) in the treatment and prognosis of multiple myeloma(MM). Methods  A total of 32 patients with multiple myeloma were included as MM group, 20 patients with monoclonal gammopathy of undetermined significance were included as monoclonal gammopathy  of undetermined significance(MGUS) group, and 20 healthy subjects were included as healthy control group. The differences of lactate dehydrogenase (LDH),  β2microglobulin (β2MG), globulin(GLB) and TK1 levels in  three groups were analyzed.The MM group was divided into Ⅰ,  Ⅱ,  Ⅲ stage groups according to MM internationalstaging system(ISS).The  differences of LDH, β2MG,  GLB and TK1 levels  in three groups were analyzed. The correlation between serum TK1 levels and LDH, β2MG,  GLB levels before  treatment  were  analyzed  by Pearson.  All patients in MM group were treated with chemotherapy. The TK1 expression levels were compared amomg CR/PR/SD/PD patients.The median survival of different TK1 levels in treatment group were analyzed. The effect of serum TK1 in the treatment and prognosis of patients with MM were analyzed.Results  The levels of serum β2MG, GLB, LDH and TK1 in MM group had significant difference with those in MGUS group and healthy control group(P<0.05). The levels of serum β2MG, GLB, LDH and TK1 levels in stage Ⅱ and  Ⅲ  had significant difference with those in stage Ⅰ(P<0.05). The levels of serum β2MG, GLB, LDH and TK1 in stage Ⅲ had significant difference with those in stage Ⅱ(P<0.05) .Serum TK1  levels were positively correlated with the levels of β2MG, GLB, LDH. After treatment,  TK1 expression level of CR/PR patients decreased significantly (P<0.05). The overall survival  rate in TK1<4.97 pmol/L and  TK1≥4.97  pmol/L groups were 64.7% and 20.0%  according to the  survival curve of KaplanMeier(P<0.05). Conclusion  The  serum levels of TK1 in patients with MM were significantly higher, and the level of TK1 has a certain reference significance for the evaluation of therapeutic effect, and affects the prognosis of  MM  patients.

Key words: multiple myeloma;thymidine kinase, monoclonal gammopathy of undetermined significance